Unlock instant, AI-driven research and patent intelligence for your innovation.

Preparation method and application of anti-human alpha fetoprotein (AFP) single-chain antibody and fusion antigen peptide

A single-chain antibody and inclusion body technology, applied in the field of bioengineering, can solve the problems of poor diffusion into tumors, limited target presentation and tumor antagonism, and weak vascular permeability.

Inactive Publication Date: 2013-09-25
CHINA PHARM UNIV
View PDF1 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Due to the large molecular weight, weak vascular permeability, and poor ability to diffuse into tumors, the intact antibodies used for tumor biotherapy limit their targeted presentation and tumor antagonism application effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method and application of anti-human alpha fetoprotein (AFP) single-chain antibody and fusion antigen peptide
  • Preparation method and application of anti-human alpha fetoprotein (AFP) single-chain antibody and fusion antigen peptide
  • Preparation method and application of anti-human alpha fetoprotein (AFP) single-chain antibody and fusion antigen peptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1: Animal immunization

[0029] Human alpha-fetoprotein was dissolved in normal saline, mixed with an equal volume of Freund's complete adjuvant, fully emulsified, and inoculated into the abdominal cavity of BALB / c mice (provided by the Comparative Medicine Center of Yangzhou University, SCXK (Su) 2007-0001). 10 μg AFP protein / 200 μL / body; after the basic immunization, the same antigen dose was mixed with an equal volume of Freund’s incomplete adjuvant for booster immunization at intervals of two weeks; one week after the second booster immunization, the immune system was measured by indirect ELISA method Mouse antiserum titers. The normal mouse serum was used as the negative control, and the determination was carried out with the judgment standard of (measurement well A value-blank value) / (negative control well A value-blank value)≥2.1. The end point titers of mouse antiserum were all above 1:12,8000.

[0030] The mouse with the highest serum hAFP-specific an...

Embodiment 2

[0031] Embodiment 2: Preparation of monoclonal antibody

[0032] 1. Cell Fusion

[0033] Cell fusion adopts the polyethylene glycol method: aseptically take the spleen of the mouse immunized as described in Example 1, make a cell suspension, centrifuge, and count the cells; divide 1×10 8 splenocytes with 2 x 10 7 Mix SP2 / 0 cells, centrifuge at 1000rpm for 10min, discard the supernatant, and place the centrifuge tube in a 37°C water bath; take 1ml of 50% PEG preheated to 40°C and slowly add it dropwise to the cell pellet, and suspend the cells with the basal medium ; Centrifuge at 1000rpm for 10min, discard the supernatant, add HAT medium to resuspend the cells, aliquot them into 96-well cell culture plates, and place the culture plates at 37°C and 5% CO 2 Culture in a humidified cell incubator, replace 1 / 2 of the culture medium in the culture plate well with fresh HAT after 5 days, and replace the HAT with HT medium after 10 days.

[0034] 2. Screening and cloning culture o...

Embodiment 3

[0037] Example 3: Construction of anti-human alpha-fetoprotein single-chain antibody

[0038] 1. Cell culture and identification: The hybridoma cells secreting anti-human alpha-fetoprotein monoclonal antibody were cultured in complete RPMI1640 medium containing 10% calf serum. The mixed gas containing 5% CO2 in the incubator was used to identify the specificity and affinity of the monoclonal antibody in the culture supernatant by ELISA method.

[0039]2. Cloning of the light chain and heavy chain variable region genes of the anti-human alpha-fetoprotein monoclonal antibody: Take a well-grown hybridoma cell line, extract total RNA with Trizol reagent, reverse transcribe to synthesize cDNA, and use PCR technology in the reaction system Add cDNA and a set of antibody antibody light chain or heavy chain variable region primers, 10×PCR reaction buffer, final concentration of 2.5nM dNTP, 0.5μL primeStar polymerase, and the total reaction system is 50uL. Perform 30 circular reactions...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an anti-human alpha fetoprotein single-chain antibody. The invention also relates to a preparation method of hepatocellular carcinoma antigen peptide fused with the anti-human alpha fetoprotein single-chain antibody. The invention further relates to usage of the anti-human alpha fetoprotein single-chain antibody and the hepatocellular carcinoma antigen peptide fused with the anti-human alpha fetoprotein single-chain antibody in treatment of neoplastic diseases.

Description

technical field [0001] The invention belongs to the field of bioengineering, and specifically relates to a single-chain antibody that can specifically bind to liver cancer marker antigen AFP, and also relates to a preparation method and application of the single-chain antibody. Background technique [0002] Hepatocellular carcinoma (HCC) is one of the common malignant tumors. Its incidence in my country is second only to gastric cancer. About 110,000 people die from liver cancer every year in my country, accounting for 45% of the world's liver cancer deaths. The annual survival rate is also the lowest among all tumors. In the past 30 years, despite the comprehensive application of various treatment methods such as surgery, radiotherapy and chemotherapy, the survival rate of patients has not improved much due to the lack of specificity, and it is imperative to explore new treatment methods [1] . [0003] Alpha-fetoprotein (α-fetoprotein, AFP) is a highly specific protein exp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/18C12N15/13C12N15/70C12N1/21C12P21/08C07K19/00G01N33/68G01N33/577G01N33/574A61K39/395A61K39/00A61P35/00A61P1/16
Inventor 高向东姬晓南冯丽亚姚文兵张瑜
Owner CHINA PHARM UNIV